sabato, 13 luglio 2024
18 Marzo 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

March 15, 2019 – EMA’s safety committee (PRAC) has started a review of medicines containing fluorouracil (also known as 5-fluorouracil or 5-FU) and the related medicines capecitabine, tegafur and flucytosine, which can be converted to fluorouracil in the body. Fluorouracil (given by injection), capecitabine and tegafur are cancer medicines, whereas topical (applied to the skin) fluorouracil is used for various skin conditions; flucytosine is a medicine used in … (leggi tutto)